Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

This publication has 24 references indexed in Scilit:

• Essential medicines for universal health coverage
  The Lancet, 2017
• ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
  Annals of Oncology, 2016
• Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
  The Lancet Oncology, 2016
• Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes
  Journal of Clinical Oncology, 2016
• The Strength of Association Between Surrogate End Points and Survival in Oncology
  JAMA Internal Medicine, 2015
• Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
  The Lancet, 2015
• Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries
  The Lancet Oncology, 2014
• Concept of essential medicines and rational use in public health
  Indian Journal of Community Medicine, 2010
• Catastrophic health payments and health insurance: Some counterintuitive evidence from one low-income country
  Health Policy, 2007
• Optimal payment systems for health services
  Journal of Health Economics, 1990